Top

Published in:

01-04-2005

Osteoprotegerin Treatment Impairs Remodeling and Apparent Material Properties of Callus Tissue without Influencing Structural Fracture Strength

Authors: M. Ulrich-Vinther, T.T. Andreassen

Published in: Calcified Tissue International | Issue 4/2005

Abstract

The influence of osteoprotegerin (OPG) treatment on callus formation, callus tissue structural strength, apparent material properties, and histology of tibia fractures in rats was investigated after 3 weeks and 8 weeks of healing. OPG was given intravenously (10 mg/kg twice weekly) during the entire observation period, and control animals with fractures received vehicle only. When compared with control fractures after 3 weeks of healing, OPG treatment reduced the number of osteoclasts in the callus tissue (93%, P < 0.001) and hampered resorption of genuine cortical bone in the fracture line; OPG treatment did not influence callus dimensions, callus bone mineral content (BMC), fracture structural strength, or callus tissue apparent material properties. When compared with control fractures after 8 weeks of healing; OPG treatment reduced the number of osteoclasts in callus tissue (92%, P < 0.001), augmented callus dimensions (anteriorposterior diameter: 12%, P = 0.034, mediolateral diameter: 13%, P = 0.013), and increased callus BMC (50%, P = 0.007); OPG treatment hampered deposition of new woven bone at the fracture line of the genuine cortical bone (new woven bone present in all vehicle animals, but only in 13% of the OPG-treated animals (P < 0.001)); OPG treatment did not influence structural strength of the fractures, but decreased apparent material properties of the callus tissue (ultimate stress: 51%, P < 0.001; elastic modulus: 42%, P = 0.033). The experiment demonstrates that OPG treatment does not influence the early callus expansion and fracture strength. However, during the subsequent period of remodelling, OPG treatment impairs the normal remodeling and consolidation processes.

Hofbauer, LC, Heufelder, AE 2001Role of receptor activator of nuclear .factor-kappaB ligand and osteoprotegerin in bone cell biologyJ Mol Med79243253CrossRef

Schwarz, EM, O’Keefe, RJ 2000Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealedCurr Opin Orthop11329335CrossRef

Teitelbaum, SL 2000Bone resorption by osteoclastsScience28915041508CrossRef

Simonet, WS, Lacey, DL, Dunstan, CR, Kelley, M, Chang, MS, Luthy, R, Nguyen, HQ, Wooden, S, Bennett, L, Boone, T, Shimamoto, G, DeRose, M, Elliott, R, Colombero, A, Tan, HL, Trail, G, Sullivan, J, Davy, E, Bucay, N, Renshaw-Gegg, L, Hughes, TM, Hill, D, Pattison, W, Campbell, P, Boyle, WJ 1997Osteoprotegerin: a novel secreted protein involved in the regulation of bone densityCell89309319CrossRef

Shimizu-Ishiura, M, Kawana, F, Sasaki, T 2002Osteoprotegerin administration reduces femoral bone loss in ovariectomized mice via impairment of osteoclast structure and functionJ Electron Microsc51315325CrossRef

Kong, YY, Feige, U, Sarosi, I, Bolon, B, Tafuri, A, Morony, S, Capparelli, C, Li, J, Elliott, R, McCabe, S, Wong, T, Campagnuolo, G, Moran, E, Bogoch, ER, Van, G, Nguyen, LT, Ohashi, PS, Lacey, DL, Fish, E, Boyle, WJ, Penninger, JM 1999Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature402304309CrossRef

Morony, S, Capparelli, C, Sarosi, I, Lacey, DL, Dunstan, CR, Kostenuik, PJ 2001Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasisCancer Res6144324436PubMed

Capparelli, C, Kostenuik, PJ, Morony, S, Starnes, C, Weimann, B, Van, G, Scully, S, Qi, M, Lacey, DL, Dunstan, CR 2000Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancyCancer Res60783787PubMed

Zhang, J, Dai, J, Qi, Y, Lin, DL, Smith, P, Strayhorn, C, Mizokami, A, Fu, Z, Westman, J, Keller, ET 2001Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the boneJ Clin Invest10712351244CrossRef

10.

Ulrich-Vinther, M, Carmody, EE, Goater, JJ, Søballe, K, O’Keefe, RJ, Schwarz, EM 2002Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysisJ Bone Joint Surg Am8414051412CrossRef

11.

Goater, JJ, O’Keefe, RJ, Rosier, RN, Puzas, JE, Schwarz, EM 2002Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysisJ Orthop Res20169173CrossRef

12.

Bekker, PJ, Holloway, D, Nakanishi, A, Arrighi, M, Leese, PT, Dunstan, CR 2001The effect of a single dose of osteoprotegerin in postmenopausal womenJ Bone Miner Res16348360CrossRef

13.

Kon, T, Cho, TJ, Aizawa, T, Yamazaki, M, Nooh, N, Graves, D, Gerstenfeld, LC, Einhorn, TA 2001Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healingJ Bone Miner Res1610041014CrossRef

14.

Andreassen, TT, Fledelius, C, Ejersted, C, Oxlund, H 2001Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormoneActa Orthop Scand12304307CrossRef

15.

Andreassen, TT, Ejersted, C, Oxlund, H 1999Intermittent parathyroid hormone (1–34) treatment increases callus formation and mechanical strength of healing rat fracturesJ Bone Miner Res14960968CrossRef

16.

Andreassen, TT, Jorgensen, PH., Flyvbjerg, A, Orskov, H, Oxlund, H 1995Growth hormone stimulates bone formation and strength of cortical bone in aged ratsJ Bone Miner Res1010571067CrossRef

17.

Erben, RG 1997Embedding of bone samples in methylmethacrylate: an improved method suitable for bone histomorphometry, histochemistry, and immunohistochemistryJ Histochem Cytochem45307313CrossRef

18.

Hayes, WC 1991 Biomechanics of cortical and trabecullar bone: Implications for assessment of fracture riskMow, VCHayes, WC eds. Basic Orthopaedic BiomechanicsRaven PressNew York93142

19.

Andreassen, TT, Willick, GE, Morley, P, Whitfield, JF 2004Treatment with parathyroid hormone hPTH(1–34), hPTH(1–31), and monocyclic hPTH(1–31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increaseCalc Tissue Int74351356CrossRef

20.

Flick, LM, Weaver, JM, Ulrich-Vinther, M, Abuzzahab, F, Zhang, X, Dougall, WC, Anderson, D, O’Keefe, RJ, Schwarz, EM 2003Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healingJ Orthop Res21676684CrossRef

21.

Lenehan, TM, Balligand, M, Nunamaker, DM, Wood, FE,Jr 1985Effect of EHDP on fracture healing in dogsJ Orthop Res3499507CrossRef

22.

Nyman, MT, Paavolainen, P, Lindholm, TS 1993Clodronate increases the calcium content in fracture callus. An experimental study in ratsArch Orthop Trauma Surg112228231CrossRef

23.

Nyman, MT, Gao, T, Lindholm, TC, Lindholm, TS 1996Healing of a tibial double osteotomy is modified by clodronate administrationArch Orthop Trauma Surg115111114CrossRef

24.

Peter, CP, Cook, WO, Nunamaker, DM, Provost, MT, Seedor, JG, Rodan, GA 1996Effect of alendronate on fracture healing and bone remodeling in dogsJ Orthop Res147479CrossRef

25.

Madsen, JE, Berg-Larsen, T, Kirkeby, OJ, Falch, JA, Nordsletten, L 1998No adverse effects of clodronate on fracture healing in ratsActa Orthop Scand69532536CrossRef

26.

Li, J, Mori, S, Kaji, Y, Mashiba, T, Kawanishi, J, Norimatsu, H 1999Effect of bisphosphonate (incadronate) on fracture healing of long bones in ratsJ Bone Miner Res14969979CrossRef

27.

Li, J, Mori, S, Kaji, Y, Kawanishi, J, Akiyama, T, Norimatsu, H 2000Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in ratsJ Bone Miner Res1520422051CrossRef

28.

Li, C, Mori, S, Li, J, Kaji, Y, Akiyama, T, Kawanishi, J, Norimatsu, H 2001Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing ratsJ Bone Miner Res16429436CrossRef

29.

Cao, Y, Mori, S, Mashiba, T, Westmore, MS, Ma, L, Sato, M, Akiyama, T, Shi, L, Komatsubara, S, Miyamoto, K, Norimatsu, H 2002Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized ratsJ Bone Miner Res1722372246CrossRef

30.

Koivukangas, A, Tuukkanen, J, Kippo, K, Jamsa, T, Hannuniemi, R, Pasanen, I, Vaananen, K, Jalovaara, P 2003Long-term administration of clodronate does not prevent fracture healing in ratsClin Orthop408268278CrossRef

31.

Tarvainen, R, Olkkonen, H, Nevalainen, T, Hyvonen, P, Arnala, I, Alhava, E 1994Effect of clodronate on fracture healing in denervated ratsBone15701705CrossRef

32.

Kostenuik, PJ, Capparelli, C, Morony, S, Adamu, S, Shimamoto, G, Shen, V, Lacey, DL, Dunstan, CR 2001OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized ratsEndocrinology14242954304CrossRef

33.

Capparelli C-Morony, S, Warmington, K, Adamu, S, Lacey, D, Dunstan, CR, Stouch, B, Martin, S, Kostenuik, PJ 2003Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in ratsJ Bone Miner Res18852858CrossRef

Title: Osteoprotegerin Treatment Impairs Remodeling and Apparent Material Properties of Callus Tissue without Influencing Structural Fracture Strength
Authors: M. Ulrich-Vinther
T.T. Andreassen
Publication date: 01-04-2005
Publisher: Springer New York
Published in: Calcified Tissue International / Issue 4/2005
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-004-0126-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2005

Increased Incidence of Vertebral Fracture in Older Female Hemodialyzed Patients with Type 2 Diabetes Mellitus

Fracture Prediction by Bone Density Measurements at Sites Other than the Fracture Site: the Contribution of BMD Correlation

Effects of Pleiotrophin (PTN) Over-expression on Mouse Long Bone Development, Fracture Healing and Bone repair

Mechanical Properties of Femoral Diaphysis and Femoral Neck of Female Rats Chronically Exposed to Various Levels of Cadmium

Mitigation of Ectopic Calcification in Osteopontin-Deficient Mice by Exogenous Osteopontin

Screening Elderly Women for Risk of Future Fractures—Participation Rates and Impact on Incidence of Falls and Fractures

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials